Pharmafile Logo
Pharmafocus logo
Advanced Search
novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019
Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …

News
20120905_ucb_02

UCB Pharma to acquire Ra Pharmaceuticals in deal valued at $2.1bn

October 10, 2019
Sales and Marketing

UCB has agreed to acquire US-based Ra Pharmaceuticals for $2.1 billion in a deal that will enable the Belgian drug …

News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …

Feature

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019
Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …

News
gsk_l_rgb

GSK partners with Lyell Immunopharma to develop cell therapies for cancer

October 9, 2019
Research and Development

GlaxoSmithKline and Lyell Immunopharma have announced a five-year agreement to jointly develop new technologies to improve cell therapies for the …

News
novartis_window

Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

October 9, 2019
Research and Development Novartis, legelizumab, pharma, urticaria

Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …

News
jj_sign_on_wall

Johnson & Johnson ordered to pay man $8bn over breast growth

October 9, 2019
Research and Development

US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over …

News

FDA approves Clinuvel’s Scenesse for rare genetic disorder

October 9, 2019
Research and Development

The US FDA has approved Clinuvel’s Scenesse (afamelanotide 16mg) as the first ever treatment for a rare genetic metabolic disorder …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

October 8, 2019
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …

News
merckincweb2

4D Pharma to collaborate with MSD in vaccine development

October 8, 2019
Manufacturing and Production

4D pharma, a leader in the development of live biotherapeutics, has announced it has entered into a research collaboration to …

News
national_multiple_sclerosis_society_move_it_

Multiple Sclerosis Society launches fundraising appeal to raise £100m

October 8, 2019
Manufacturing and Production

The MS Society has launched a hard-hitting public appeal to raise £100m to stop multiple sclerosis. The Stop MS Appeal …

News
novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

News

Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

October 8, 2019
Manufacturing and Production

Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate …

News

Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula

October 7, 2019
Sales and Marketing

The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate …

News
merdad_parsey

Gilead appoints Merdad Parsey as Chief Medical Officer

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …

Appointment

Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma

Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …

Feature
oxycontinoverdoses_798

Sacklers made up to $13 billion in profits from Purdue Pharma

October 7, 2019
Sales and Marketing

New court records filed in Purdue Pharma’s ongoing bankruptcy case show that the owners, the Sackler family, received $12 billion …

News
merckwindow_web

Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer

October 7, 2019
Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …

News

Pfizer reports positive phase 3 data in atopic dermatitis

October 7, 2019
Sales and Marketing

Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 …

News
7359dba7-e1da-4eb4-8765-58da6178899b

Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E

October 7, 2019
Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta

Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …

News
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026